How to buy KemPharm stock (KemPharm)

KemPharm is currently traded as an over-the-counter (OTC) stock, which means that some shares are available, but not easy to access. The company plans to list on the Nasdaq, which will make it easy to buy shares from any major brokerage account. Here's how.

Our top picks for where to buy KemPharm stock

Buy KemPharm stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

KemPharm stock price (NASDAQ: KMPH)

Use our graph to track the performance of KMPH stocks over time.

KemPharm shares at a glance

• Key figures

Information last updated 2024-06-30.

52-week range	$0.00 - $0.00
50-day moving average more info button	$5.32
200-day moving average more info button	$5.27
Wall St. target price	$22.33
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-0.91

Is it a good time to buy KemPharm stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

KemPharm financials

Revenue TTM	$10.7 million
Gross profit TTM	$26.6 million
Return on assets TTM	-8.97%
Return on equity TTM	-31.24%
Profit margin	0%
Book value	$2.72
Market Capitalization more info button	$200.5 million

TTM: trailing 12 months

KemPharm share dividends

We're not expecting KemPharm to pay a dividend over the next 12 months.

You may also wish to consider:

• Perrigo Company (PRGO.US) (4.29% forward annual dividend yield)
• Pfizer (PFE.US) (6.53% forward annual dividend yield)
• Sanofi ADR (SNY.US) (4.27% forward annual dividend yield)

Have KemPharm's shares ever split?

KemPharm's shares were split on a 1:16 basis on 27 December 2020 . So if you had owned 16 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your KemPharm shares – just the quantity. However, indirectly, the new 1500% higher share price could have impacted the market appetite for KemPharm shares which in turn could have impacted KemPharm's share price.

KemPharm share price volatility

Over the last 12 months, KemPharm's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while KemPharm's is 2.1586. This would suggest that KemPharm's shares are significantly more volatile than the average for this exchange and represent a higher risk.

To put KemPharm's beta into context you can compare it against those of similar companies.

• Perrigo Company (PRGO.US): 0.484
• Pfizer (PFE.US): 0.615
• Sanofi ADR (SNY.US): 0.445

KemPharm overview

Zevra Therapeutics, Inc. , a rare disease therapeutics company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.

Frequently asked questions

What percentage of KemPharm is owned by insiders or institutions?
Currently 10.29% of KemPharm shares are held by insiders and 17.687% by institutions. How many people work for KemPharm?
Latest data suggests 24 work at KemPharm. When does the fiscal year end for KemPharm?
KemPharm's fiscal year ends in December. Where is KemPharm based?
KemPharm's address is: 1180 Celebration Boulevard, Celebration, FL, United States, 34747 What is KemPharm's ISIN number?
KemPharm's international securities identification number is: US4884452065 What is KemPharm's CUSIP number?
KemPharm's Committee on Uniform Securities Identification Procedures number is: 488445107